RT Journal Article
SR Electronic
T1 Placental vascular remodeling in pregnant women with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.01.21259860
DO 10.1101/2021.07.01.21259860
A1 Gychka, Sergiy G.
A1 Kuchyn, Iurii L.
A1 Savchuk, Tetyana V.
A1 Nikolaienko, Sofia I.
A1 Zhezhera, Volodymyr M.
A1 Chermak, Ihor I.
A1 Suzuki, Yuichiro J.
YR 2021
UL http://medrxiv.org/content/early/2021/07/03/2021.07.01.21259860.abstract
AB Severe acute respiratory syndrome coronavirus 2 has been causing the pandemic of coronavirus disease 2019 (COVID-19) that has so far resulted in over 180 million infections and nearly 4 million deaths. This respiratory virus uses angiotensin-converting enzyme 2 as a receptor to enter host cells, exhibiting a unique feature that affects various tissues in addition to the lungs. The present study reports that the placental arteries from women who gave birth to live full-term newborns while developing of COVID-19 during pregnancy exhibit severe vascular wall thickening and the occlusion of the vascular lumen. A morphometric analysis of the placental arteries stained with hematoxylin and eosin suggest a 2-fold increase in wall thickness and a 5-fold decrease in the lumen area. Immunohistochemistry with α-smooth muscle actin and Masson’s trichrome staining showed that such placental vascular remodeling in COVID-19 is associated with smooth muscle proliferation and fibrosis. Placental vascular remodeling may represent a mechanism of the clinical problems associated with childbirth in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the National Institutes of Health (grant numbers R21AI142649, R03AG059554, R03AA026516) to Dr. Suzuki.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical studies were approved by the regional committee for medical research ethics in Kiev, Ukraine.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available from corresponding authors upon request.ACE2angiotensin-converting enzyme 2COVID-19coronavirus disease 2019H&Ehematoxylin and eosinSARS-CoV-2severe acute respiratory syndrome coronavirus 2